NYPOZI Q Code: Q5148

Drug & Product Overview

HCPCS Descriptor Injection, filgrastim-txid (nypozi), biosimilar, 1 microgram

HCPCS Added Date April 1, 2025

Manufacturer Cipla

Route of Administration Intravenous, Subcutaneous

Generic Status Single-Source; Branded

Dosage Type Single-Dose

Dosage Form Injection

About Nypozi

Nypozi is a medication aligned to the HCPCS Q Code: Q5148 for billing, pricing, and reimbursement purposes in the United States. It is an Oncology Colony Stimulating Factor drug administered via the intravenous or subcutaneous routes and manufactured by Cipla.

Manufacturers, reach out to us to add more information.

NDC Code Information

Based on publicly available CMS files. The list of NDCs below is not exhaustive.

NDC Code	Package	Manufacturer	HCPCS Units	WAC	AWP
69097-0429-67	480 UG Nypozi Intravenous Injection 480 UG/480UG - 1 SYRINGE, GLASS in 1 CARTON (69097-429-67) / 480 ug in 1 SYRINGE, GLASS	Cipla USA Inc.	480	$478.29 $0.996 / unit	$573.95 $1.196 / unit
69097-0429-96	480 UG Nypozi Intravenous Injection 480 UG/480UG - 10 SYRINGE, GLASS in 1 CARTON (69097-429-96) / 480 ug in 1 SYRINGE, GLASS	Cipla USA Inc.	4800	$4,782.84 $0.996 / unit	$5,739.41 $1.196 / unit
69097-0430-67	300 UG Nypozi Intravenous Injection 300 UG/300UG - 1 SYRINGE, GLASS in 1 CARTON (69097-430-67) / 300 ug in 1 SYRINGE, GLASS	Cipla USA Inc.	300	$300.33 $1.001 / unit	$360.40 $1.201 / unit
69097-0430-96	300 UG Nypozi Intravenous Injection 300 UG/300UG - 10 SYRINGE, GLASS in 1 CARTON (69097-430-96) / 300 ug in 1 SYRINGE, GLASS	Cipla USA Inc.	3000	$3,003.35 $1.001 / unit	$3,604.02 $1.201 / unit

Effective 1/12/26 (WAC & AWP)

Login for the full NDC crosswalk View pricing, complete NDC-to-HCPCS alignments, and package details.

Login →

Nypozi Pricing & Reimbursement

Q5148 Private Payer Reimbursement

$1.03 / HCPCS unit as of Jan 2026

National median reimbursement across major commercial payers.

Create an account on PayerPrice for more information →

Historical Graphing and Billing Calculator

NDC Package

HCPCS Units

Markup / Markdown

%

Common:

Estimates only. Payer reimbursement varies by contract, site of care, and sequestration.

Estimated Reimbursement

Filgrastim Biosimilar Information:

Nypozi Approval Date: June 28, 2024

Product Name	HCPCS Code	Active Ingredient	BLA Type
Neupogen	J1442	Filgrastim	351(a) Originator Product
Zarxio	Q5101	Filgrastim	351(k) Biosimilar
Nivestym	Q5110	Filgrastim	351(k) Biosimilar
Releuko	Q5125	Filgrastim	351(k) Biosimilar
Nypozi	Q5148	Filgrastim	351(k) Biosimilar
Filkri	Q5172	Filgrastim	351(k) Biosimilar

Nypozi CPT Administration Codes

CPT Code	Description
96372	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intramuscular
96401	Chemotherapy administration, subcutaneous or intramuscular; non-hormonal anti-neoplastic

Not on the CMS JW / JZ list

This product is new and does not yet appear on the CMS list of HCPCS pertaining to single-dose containers. Wastage billing guide →

Nypozi Medically Unlikely Edits (MUE)

The most billing units of Q5148 Medicare will pay for one patient in one day, as published by CMS. 1 unit = 1 mcg.

Practitioner Office & Hospital Outpatient

1,500 units / day

= 1,500 mcg per day

MAI 3 · Date of Service Edit: Clinical. Per-day limit based on clinical expectations; excess units are denied but may be appealed with documentation of medical necessity. See all MUE limits →

Nypozi Clinical Information

Indications and drug classification.

Treated Diseases & Conditions

This list of indications is not exhaustive and may be subject to errors. The information on BuyandBill.com is intended for informational purposes only and should not be used for medical advice.

Acute myeloid leukemia receiving induction or consolidation chemotherapy Autologous peripheral blood progenitor cell collection and therapy Hematopoietic Syndrome of Acute Radiation Syndrome Mobilization of autologous hematopoietic progenitor cells for collection by leukapheresis Nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs Nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation Severe chronic neutropenia – congenital neutropenia Severe chronic neutropenia – idiopathic or cyclic neutropenia Severe chronic neutropenia — congenital neutropenia Severe chronic neutropenia — idiopathic or cyclic neutropenia

Drug Class

Granulocyte Colony-Stimulating Factor [CS]Increased Myeloid Cell Production [PE]Leukocyte Growth Factor [EPC]

Frequently Asked Questions

Is there a manufacturer-published NYPOZI billing and coding guide?

Our team has not identified a manufacturer-published source of billing and coding information for NYPOZI.

What are the available NYPOZI patient assistance programs?

Our team has not identified a manufacturer-published source of patient assistance information for NYPOZI.

Where can I find NYPOZI prescribing information?

NYPOZI prescribing information can be found at the link below. Visit Here →

Where can I find NYPOZI side effect information?

Our team has not identified a source of side effect information for NYPOZI.

Does billing NYPOZI require JZ/JW wastage modifiers?

CMS does not include NYPOZI (Q5148) on its list of HCPCS pertaining to single-dose containers. Per CMS guidelines, the JZ/JW wastage modifiers may not apply when billing Q5148. For more information, visit the link below.

About BuyandBill.com:

The BuyandBill.com team is dedicated to delivering high-quality coding and billing information for office-administered drugs. We continuously research HCPCS-coded medications to expand our resources and ensure data accuracy. Manufacturers: click here to sponsor your medication, and we will ensure the most accurate and detailed information is displayed.